This study will assess the efficacy and safety of different doses of ACT-129968 in adult patients with seasonal allergic rhinitis, due to mountain cedar pollen.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
579
ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
ACT-129968 (Dose 4) \& matching placebo administered orally once daily
Ceterizine administered once daily
Clinical Investigative Site 7905
Austin, Texas, United States
Clinical Investigative Site 7907
Kerrville, Texas, United States
Clinical Investigative Site 7903
New Braunfels, Texas, United States
Clinical Investigative Site 7901
San Antonio, Texas, United States
To demonstrate a change in Daytime Nasal Symptom Score while taking Dose 3 of ACT-129968 versus placebo
Time frame: Baseline to week 2
To demonstrate a change in Daytime Nasal Symptom Score while taking either Dose 1, Dose 2, or Dose 4 of ACT-129968 verses placebo.
Time frame: Baseline to week 2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Matching placebo administered twice daily.
Clinical Investigative Site 7902
San Antonio, Texas, United States
Clinical Investigative Site 7904
San Antonio, Texas, United States
Clinical Investigative Site 7906
San Antonio, Texas, United States